Neuronascent, Inc., which is developing novel, neurogenic small-molecule drugs for neurodegenerative diseases, has announced its participation in a discovery agreement with Russian biotech start-up ChemRar. ChemRar develops small-molecule modulators for developmental pathways, as well as stem cells. Under the new collaboration, Neuronascent, using its drug discovery platform for neurogenesis and neuroprotection, will screen certain ChemRar’s proprietary developmental pathway inhibitors. The partnership is meant to pair ChemRar’s focus on discovery and translational research with Neuronascent’s emphasis on the discovery of new neuroprotective therapy candidates.
Click here to read more.Share this: